AgomAb Therapeutics Identifies Regenerative Pathway Modulators, Attracts Investors

HGF Mimetic Agonistic Antibody Under Development

10 Mar 2021

• By John Davis

Two US VCs have led a large $75m series B financing of Belgium’s AgomAb Therapeutics, which is gaining traction in developing antibodies that act on the HGF-MET pathway, potentially reversing fibrosis and allowing damaged tissues to regain function.

embryonic stem cells — • Source: Shutterstock

Developing antibodies that act as HGF-mimetics differentiates AgomAb Therapeutics NV’s approach from potential small-molecule competitors in the hepatocyte growth factor (HGF)/regeneration field, and VCs including two from the US have just raised $74m in a series B round to advance the company’s pipeline and to move its lead compound, AGMB-101, into the clinic.

The hefty funding follows a $18.7m-plus series A round completed in 2019, and gives the Ghent, Belgium-based biotech a certain...